51638-91-6

Usage

Uses

Used in Pharmaceutical Industry:
(3aR,4R,5R,6aS)-2-oxo-4-((E)-3-oxo-4-phenoxybut-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate is used as a potential pharmaceutical compound for its bioactive properties due to its unique structure and functional groups.
Used in Chemical Research:
(3aR,4R,5R,6aS)-2-oxo-4-((E)-3-oxo-4-phenoxybut-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate is used as a subject of chemical research to explore its potential applications and effects in various fields, given its complex structure and the presence of multiple functional groups.
Used in Pesticide Development:
(3aR,4R,5R,6aS)-2-oxo-4-((E)-3-oxo-4-phenoxybut-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate is used as a potential component in the development of new pesticides, leveraging the presence of a phenoxy group, which is common in certain pesticides and known to be metabolized by the body.

Upstream product

• 40665-68-7 dimethyl (3-phenoxy-2-oxopropyl)phosphonate 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 

Downstream Products

• 209861-00-7 (3aR,4R,5R,6aS)-4-((E)-3,3-difluoro-4-phenoxybutan-1-en-1-yl)-hexahydro-2-oxo-2H-cyclopenta[b]furan-5-yl benzoate 
• 51638-92-7 (3aR,4R,5R,6aS)-5-(benzoyloxy)hexahydro-4-((3R)-3-hydroxy-4-phenoxy-1(E)-butenyl)-2H-cyclopentafuran-2-one 
• 51705-18-1 [3aR,4R(1E,3S),5R,6aS]-5-benzoyloxy-4-(3-hydroxy-4-phenoxy-1-buten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one 
• 59618-87-0 [3aR,4R(1E),5R,6aS]-5-(benzoyloxy)-4-[4-phenoxy-3,3-(ethylenedioxy)butenyl]-hexahydro-2H-cyclopenta[b]furan-2-one 
• 1449413-13-1 C₂₂H₂₈F₂O₅*C₁₂H₂₃N 
• 209860-87-7 tafluprost 
• 209860-88-8 AFP-172 
• 209861-02-9 (3aR,4R,5R,6aS)-4-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2,5-diol 
• 209861-01-8 (3aR,4R,5R,6aS)-4-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-5-hydroxyhexahydro-2H-cyclopenta[b]furan-2-one 
• 208112-11-2 (5Z)-(9S,11R,15R)-9-hydroxy-15-fluoro-16-phenoxy-11-(tetrahydropyran-2-yloxy)-17,18,19,20-tetranor-5-prostenoic acid isopropyl ester 
• 242464-10-4 (5Z,13E)-(9S,11R,15RS)-15-fluoro-9-hydroxy-16-phenoxy-11-(tetrahydropyran-2-yloxy)-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester 
• 242464-07-9 (Z)-7-[(1R,2R,3R,5S)-2-((E)-3-Fluoro-4-phenoxy-but-1-enyl)-5-hydroxy-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hept-5-enoic acid 

Relevant academic research and scientific papers

Identification and efficient synthetic method for preparation of cyclopentane-1,3-diol impurity in tafluprost drug

In present work, the isolation, synthesis and characterization of the identified triol impurity present in tafluprost is described. This investigation helps to avoid formation of impurity by control the reaction and its leads to improving high yields of t

METHOD OF PURIFICATION OF PROSTAGLANDINS INCLUDING FLUORINE ATOMS BY PREPARATIVE HPLC

The present invention discloses a method of purification of prostaglandins including fluorine atoms by using preparative HPLC. Tafluprost and Travoprost are prostaglandins including fluorine. The chemical structure of the impurities in crude Tafluprost an

AMINE SALTS OF PROSTAGLANDIN ANALOGS

The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the preparation of substant

Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168: A novel 15-deoxy-15,15-difluoroprostaglandin F2α derivative

A novel 15-deoxy-15,15-difluoro-prostaglandin(PG)F2α derivative 6 (AFP-168) has been synthesized from the Corey aldehyde in six steps. A key aspect of this route is difluorination of an enone and a stereoselective Wittig reaction. The compound shows high affinity to the FP receptor and potent activities for an anti-glaucoma agent.

Synthesis and biological properties of novel fluoroprostaglandin derivatives: Highly selective and potent agonists for prostaglandin receptors

Synthesis of novel 7,7-difluoroprostacyclin and 15-deoxy-15,15-difluoro- PGF2α derivatives will be presented. These compounds show high affinity to prostaglandin receptors and potent biological activities.

15-fluoro prostaglandins as ocular hypotensives

15-fluoro substituted analogs of PGF2αand methods of their use in treating glaucoma and ocular hypertension are disclosed.

15-ketal postaglandins for the treatment of glaucoma or ocular hypertension

A method of treating glaucoma or ocular hypertension in a patient, which comprises administering to the patient a pharmaceutically effective amount of a compound of formula I:

15-fluoro prostaglandins as acular hypotensives

15-fluoro substituted analogs of PGF2α and methods of their use in treating glaucoma and ocular hypertension are disclosed.

Difluoroprostaglandin derivatives and their use

A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: STR1 wherein A is a vinylene group or the like, R1 is an

Process for the preparation of oxaprostaglandin intermediates

In a process for the preparation of an oxaprostaglandin intermediate of the formula STR1 wherein R1 is hydrogen, alkyl, or a free or functionally modified hydroxy group; R2 and R3 are the same or different, and each is hydrogen, halogen or alkyl; R4 is alkyl or optionally substituted aryl; and n is 0, 1, 2 or 3; which comprises reacting an aldehyde of the formula STR2 wherein R1 is as defined above with an anion of the formula STR3 wherein n, R2, R3 and R4 are as defined above; and R5 is alkyl; an improvement is provided wherein the anion is added to the reaction medium in a form which consists essentially of its crystalline alkali metal salt of the formula STR4 wherein A is an alkali metal atom.